What's in Barts & The London NHS Trust's pipeline?

Barts & The London NHS Trust has 13 drugs in our index: 6 marketed, 0 filed, 2 in Phase 3, 2 in Phase 2, 2 in Phase 1.

Which companies overlap with Barts & The London NHS Trust's portfolio?

Top competitors by shared drug class: Merck Sharp & Dohme LLC, Assistance Publique - Hôpitaux de Paris, Hoffmann-La Roche, Amgen, Sun Yat-sen University.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/barts-the-london-nhs-trust.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Barts & The London NHS Trust — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Barts & The London NHS Trust pipeline: 6 marketed, 0 filed, 2 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

6 marketed 0 filed 2 Phase 3 2 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
DMARD	DMARD	marketed			Other
Envarsus	Envarsus	marketed			Other
Ergocalciferol (Vitamin D)	Ergocalciferol (Vitamin D)	marketed	Vitamin D supplement	Vitamin D receptor (VDR)	Endocrinology / Nutritional deficiency
Combined Depo-Medrone and Lidocaine	Combined Depo-Medrone and Lidocaine	marketed
Administration of paracetamol	Administration of paracetamol	marketed
Paclitaxel protein bound	Paclitaxel protein bound	marketed	Taxane; microtubule stabilizer	β-tubulin (microtubule)	Oncology
Migliol Placebo Oil	Migliol Placebo Oil	phase 3
Darbepoetin alpha	Darbepoetin alpha	phase 3	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR)	Hematology/Oncology

Therapeutic area mix

Other · 3
Oncology · 2
Endocrinology / Nutritional deficiency · 1
Hematology/Oncology · 1
Infectious Diseases · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Merck Sharp & Dohme LLC · 2 shared drug classes
Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
Hoffmann-La Roche · 2 shared drug classes
Amgen · 2 shared drug classes
Sun Yat-sen University · 2 shared drug classes
Aravive, Inc. · 1 shared drug class
Anemia Working Group Romania · 1 shared drug class
Air Force Military Medical University, China · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Barts & The London NHS Trust:

Cite this brief

Drug Landscape (2026). Barts & The London NHS Trust — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/barts-the-london-nhs-trust. Accessed 2026-05-17.